Labcorp

Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) are redefining possibilities in advanced non-small cell lung cancer (aNSCLC) therapies. Discover how the combination of these treatments is shaping the future of oncology, supported by promising data and clinical advancements. Learn more for key insights: https://spr.ly/6047sCUtW #LungCancerAwarenessMonth #ADCs

Join us at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, from Dec. 7-10. Stop by booth 455 to learn about our latest innovations and connect with the Labcorp team. We look forward to seeing you there. Learn more at https://spr.ly/6042si34M

As the Great American Smokeout approaches on Nov. 21, learn how a wellness coach can assist with a smoking cessation program and help prevent and reduce the effects of chronic obstructive pulmonary disease. Read more: https://spr.ly/6047sv45U #HealthCoaching #COPD #EmployeeWellness #HealthAndWellnessCoaching

Sangita was first drawn to Labcorp because of its scientific reputation. When she joined our oncology team, she soon saw many ways to thrive in her work with specialists and oncologists. Learn about her role on our oncology team and its impact on patients’ lives: https://spr.ly/6046sSaA6 #JoinThePursuit #HealthcareCareers #Oncology

Knowing HER2 status can help improve outcomes for people with breast cancer. That's why Labcorp and Outcomes4Me collaborated to drive awareness around HER2 status. An initial survey of patients with metastatic breast cancer revealed that half of respondents never discussed HER2 status with their providers. Learn how increased awareness of HER2 status changed this: https://spr.ly/6040s3KQp #BreastCancer

An important advancement for patients with advanced gastric or gastroesophageal junction cancers: Labcorp is now offering the first FDA-approved companion diagnostic test for identifying those who may benefit from targeted treatment with VYLOY?. Timely access to this test, made possible by our participation in Roche's Day-One readiness program, means eligible patients can potentially start appropriate therapies sooner, which could make a significant difference in their care journeys. Learn more: https://spr.ly/6043sHGCW #GastricCancer #CancerDiagnostics #PersonalizedMedicine

According to the American Diabetes Association, liver disease affects up to 70% of those with Type 2 diabetes. If you live with Type 2 diabetes, you may be at risk for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition that can lead to cirrhosis, liver cancer and heart disease. The good news is that knowing your risk can help you take control of the disease. To better understand your MASH risk and learn how you can manage it, talk to your provider about Labcorp’s testing solutions for fatty liver disease. Our comprehensive portfolio can help with diagnosis and management of MASH so you and your care team can make informed decisions for your health. Explore our profiles and related tests: https://spr.ly/6044sDvu4 #DiabetesAwarenessMonth #MASH

Discover the latest enhancements to Labcorp Global Trial Connect, designed to streamline site workflows and boost clinical trial efficiency. These updates, driven by insights from collaboration with sponsors and sites, aim to empower investigator sites to focus more on what truly matters, patient care. Your commitment to patient care is why we’re committed to redefining clinical trial delivery. Learn more: https://spr.ly/6041s6xgl #ClinicalTrials #GlobalTrialConnect

This #VeteransDay, Labcorp honors our employees and everyone around the globe who have served or are still serving in the U.S. Armed Forces. In recognition of this important day, Labcorp's Veterans Employee Resource Group (VERG) proudly hosted retired Brigadier General Joni K. Matthews who had a distinguished 36-year military career and spoke on the value veterans bring to any organization. We are also pleased to share that Labcorp has received The Military Friendly silver designation this year. The Military Friendly ratings program was started in 2003 to encourage civilian organizations to invest in programs to recruit, retain and advance veterans as employees, entrepreneurs and students. Learn more about our veteran community at Labcorp: https://spr.ly/6045SA8Pt

At Labcorp, we understand the challenges in identifying those at risk for developing MASH. That’s why we’re committed to supporting your mission of advancing liver health. Join us at the AASLD 2024 Liver Meeting as we showcase our industry-leading portfolio of MASH and MASLD diagnostics. We look forward to discussing our cutting-edge solutions, including ELF, NIS2+ and NIS4 tests, which can support your liver disease testing needs and help improve patient outcomes. Learn more: https://spr.ly/6041SfuuU #TLM24 #LiverDiseaseTesting #Hepatology #MASHTesting #MASHDiagnostics